ARA-290 has shown to help reduce HbA1c, improve cholesterol, modulate neuropathic pain and stimulate wound repair and is made of 11 amino acids that has been studied for its potential to promote blood vessel growth, tissue repair, cell survival, neuroprotection in the case of diabetic neuropathy, and alter blood pressure. ARA-290 has been proposed by researchers to exhibit anti-apoptotic, anti-inflammatory, and anti-permeability potential akin to endogenous EPO
Peptide ARA-290 has undergone numerous clinical trials, proving its efficacy and safety. One of the most extensive clinical trials involved 204 participants with diabetic neuropathy. The results show that therapy with ARA 290 leads to a significant improvement in neuropathic pain and aids in reducing the symptoms of the disease. In another study involving 90 individuals with fibromyalgia, there was a marked decrease in pain and a positive increase in the quality of life for the participants after the application of peptide ARA 290. The results from another clinical trial, in which 290 individuals participated, show that ARA 290 improves glucose metabolism in the brain, protects the nervous system from damage, and accelerates wound healing. All clinical trials of ARA 290 conducted to date provide good and promising results for the treatment of various diseases.